Literature DB >> 21506165

Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations.

Jennifer G Goldman, Darcy Marr, Lili Zhou, Bichun Ouyang, Sue E Leurgans, Elizabeth Berry-Kravis, Christopher G Goetz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21506165      PMCID： PMC3142314          DOI： 10.1002/mds.23655

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  7 in total

1.  Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease.

Authors:  C Fujii; S Harada; N Ohkoshi; A Hayashi; K Yoshizawa; C Ishizuka; T Nakamura
Journal:  Clin Genet       Date:  1999-11       Impact factor: 4.438

2.  Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study.

Authors:  C G Goetz; P F Burke; S Leurgans; E Berry-Kravis; L M Blasucci; R Raman; L Zhou
Journal:  Arch Neurol       Date:  2001-02

3.  A new genetic variant in the Sp1 binding cis-element of cholecystokinin gene promoter region and relationship to alcoholism.

Authors:  S Harada; T Okubo; M Tsutsumi; S Takase; T Muramatsu
Journal:  Alcohol Clin Exp Res       Date:  1998-05       Impact factor: 3.455

4.  Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system.

Authors:  Jennifer G Goldman; Christopher G Goetz; Elizabeth Berry-Kravis; Sue Leurgans; Lili Zhou
Journal:  Arch Neurol       Date:  2004-08

5.  Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease.

Authors:  Jian Wang; Yan-Mei Si; Zhuo-Lin Liu; Long Yu
Journal:  Pharmacogenetics       Date:  2003-06

Review 6.  Epidemiology of psychosis in Parkinson's disease.

Authors:  Gilles Fénelon; Guido Alves
Journal:  J Neurol Sci       Date:  2009-09-08       Impact factor: 3.181

7.  L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.

Authors:  R Kaiser; A Hofer; A Grapengiesser; T Gasser; A Kupsch; I Roots; J Brockmöller
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910
  7 in total
  6 in total

Review 1.  Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

Authors:  Cristina Politi; Cinzia Ciccacci; Giuseppe Novelli; Paola Borgiani
Journal:  Neuromolecular Med       Date:  2018-01-05       Impact factor: 3.843

Review 2.  Psychosis in Parkinson's Disease: A Lesson from Genetics.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Sokratis G Papageorgiou; Chiara Villa
Journal:  Genes (Basel)       Date:  2022-06-20       Impact factor: 4.141

3.  Association analysis of HLA-DRA in Chinese patients with sporadic Parkinson's disease.

Authors:  Ming-Shu Mo; You-Sheng Xiao; Zhuo-Hua Wu; Cong-Cong Sun; Li-Min Zhang; Luan Cen; Xiang Chen; Shao-Gang Qu; Xin-Ling Yang; Ping-Yi Xu
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2015-12-25

Review 4.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

5.  Cell-Cell Communication Alterations via Intercellular Signaling Pathways in Substantia Nigra of Parkinson's Disease.

Authors:  Maoxin Huang; Liang Xu; Jin Liu; Pei Huang; Yuyan Tan; Shengdi Chen
Journal:  Front Aging Neurosci       Date:  2022-02-25       Impact factor: 5.750

6.  Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions.

Authors:  Marek Droździk; Monika Białecka; Mateusz Kurzawski
Journal:  Curr Genomics       Date:  2013-12       Impact factor: 2.236
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.